Colchicine attenuates cardiac hypertrophy by targeting the macrophage-driven Interleukin-6 suppression
Molecular Immunology · 2026
DOI: 10.1016/j.molimm.2026.08.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Immunology, 2026. Verfasst von Nianwei Zhou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai Institute of Medical Ima…. Hauptthemen laut MEDLINE: Colchicine, Macrophages, Interleukin-6, Cardiomegaly. Die Arbeit nennt 54 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Key Technologies Research and Development Program.
Abstract (Originalsprache)
Hypertrophic cardiomyopathy (HCM), the most prevalent inherited cardiovascular disease, is strongly linked to progressive heart failure and sudden cardiac death (SCD). However, its underlying pathogenic mechanisms remain incompletely understood, and effective therapeutic strategies are still lacking. Here, we established two murine HCM models harboring high SCD risk-associated mutations. Single-cell RNA sequencing revealed immune activation and enhanced fibrotic remodeling in the myocardium of these models. Therefore, we hypothesized that colchicine, a widely used anti-inflammatory drug known to reduce cardiovascular events in multiple cardiac disorders, may also represent a promising therapeutic candidate for HCM. As we expected, colchicine treatment attenuated pathological remodeling in our study, as evidenced by reduced cardiomyocyte hypertrophy, decreased fibrosis, and downregulation of cardiac stress markers (Anp, Bnp) and fibrotic mediators (Ctgf, Col1a1, Col3a1). In addition, colchicine attenuated pro-inflammatory macrophage populations and suppressed IL-6 expression, thereby contributing to the preservation of cardiac function. These findings provide the first preclinical evidence that colchicine alleviates myocardial inflammation and fibrosis in HCM, underscoring its potential as a novel therapeutic strategy to reduce fibrosis, lower SCD risk, and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai Institute of Medical Imaging, Shanghai 200032, China. Electronic address: zhou.nianwei@zs-hosp…
- Department of Immunology, School of Basic Medical Sciences, Shanghai Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China. Electronic address:…
- Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai Institute of Medical Imaging, Shanghai 200032, China. Electronic address: 1475603239@qq.com.
- Institute of Medical Genetics and Genomics, Fudan University, Shanghai 200032, China. Electronic address: 23210700047@m.fudan.edu.cn.
- Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai Institute of Medical Imaging, Shanghai 200032, China. Electronic address: sunyi97er@163.com.
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai 200032, China. Electronic address: cui.xiaotong@zs-hospital.sh.cn.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Key Technologies Research and Development Program
Zitieren
APA
Zhou, N., Wang, W., Wei, X., Su, W., Sun, Y., Yu, B., Chen, H., Yang, H., Cui, X., Zhang, S., Pan, C., Chu, Y., Huang, T., Wang, L., & Shu, X. (2026). Colchicine attenuates cardiac hypertrophy by targeting the macrophage-driven Interleukin-6 suppression. Molecular Immunology. https://doi.org/10.1016/j.molimm.2026.08.005
Vancouver
Zhou N, Wang W, Wei X, Su W, Sun Y, Yu B, et al. Colchicine attenuates cardiac hypertrophy by targeting the macrophage-driven Interleukin-6 suppression. Molecular Immunology. 2026. doi:10.1016/j.molimm.2026.08.005
BibTeX
@article{Zhou2026,
author = {Zhou, Nianwei and Wang, Wenjun and Wei, Xuemei and Su, Wenkai and Sun, Yi and Yu, Baichao and Chen, Huanhao and Yang, Hui and Cui, Xiaotong and Zhang, Shuning and Pan, Cuizhen and Chu, Yiwei and Huang, Taosheng and Wang, Luman and Shu, Xianhong},
title = {Colchicine attenuates cardiac hypertrophy by targeting the macrophage-driven Interleukin-6 suppression},
journal = {Molecular Immunology},
year = {2026},
doi = {10.1016/j.molimm.2026.08.005}
}
EUVIMED